Depression/anxiety problems increased for urban, racial- and ethnic-minority children during versus six months before the pandemic

Findings seen for COVID-19 infection, hospitalization, and mortality

Screening protocol could identify candidates for neuromodulation therapies who could skip a formal in-person psychological assessment

Three-month depressive symptoms in adolescents lower with online SSIs compared with supportive control during COVID-19 pandemic

Pediatricians should inquire about child and family functioning; office visits should integrate behavioral, mental health surveillance

Sharp increase in deaths in Midwestern, Southern, Western jurisdictions; stimulant also involved in about four of 10 IMF-involved deaths

Elevated resting heart rate also associated with accelerated cognitive decline

Rare genetic variants occur more frequently in severe, extremely treatment-resistant schizophrenia versus typical schizophrenia

Amyloid-related imaging abnormalities-edema seen on brain MRI most common adverse event in participants receiving high-dose aducanumab

Likelihood of developing POU increased for those with history of drug abuse, preoperative muscle relaxant or benzodiazepine use